182 related articles for article (PubMed ID: 28515254)
21. The role of JAK2 inhibitors in MPNs 7 years after approval.
Passamonti F; Maffioli M
Blood; 2018 May; 131(22):2426-2435. PubMed ID: 29650801
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
23. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes R; Mesa RA
Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
[TBL] [Abstract][Full Text] [Related]
24. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
25. Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
How J; Story C; Connors JM
Postgrad Med; 2021 Jun; 133(5):508-516. PubMed ID: 33480813
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
27. The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.
Kim SY; Bae SH; Bang SM; Eom KS; Hong J; Jang S; Jung CW; Kim HJ; Kim HY; Kim MK; Kim SJ; Mun YC; Nam SH; Park J; Won JH; Choi CW
Korean J Intern Med; 2021 Jan; 36(1):45-62. PubMed ID: 33147902
[TBL] [Abstract][Full Text] [Related]
28. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
29. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
31. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
32. Future therapies for the myeloproliferative neoplasms.
Scherber R; Mesa RA
Curr Hematol Malig Rep; 2011 Mar; 6(1):22-7. PubMed ID: 21080242
[TBL] [Abstract][Full Text] [Related]
33. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Bose P; Verstovsek S
Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
[TBL] [Abstract][Full Text] [Related]
34. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
Sankar K; Stein BL
J Natl Compr Canc Netw; 2018 Dec; 16(12):1539-1545. PubMed ID: 30545998
[TBL] [Abstract][Full Text] [Related]
35. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
36. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
37. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
38. Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs).
Pemmaraju N; Mesa R
Hematology Am Soc Hematol Educ Program; 2015; 2015():649-51. PubMed ID: 26637784
[TBL] [Abstract][Full Text] [Related]
39. Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.
Kiladjian JJ
Am Soc Clin Oncol Educ Book; 2015; ():e389-96. PubMed ID: 25993201
[TBL] [Abstract][Full Text] [Related]
40. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]